We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

18 hedge funds and large institutions have $691K invested in Processa Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.01% → 0.01% (-0%)

18% less funds holding

Funds holding: 22 → 18 (-4)

19% less capital invested

Capital invested by funds: $853K → $691K (-$161K)

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
18
Holders Change
-4
Holders Change %
-18.18%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$167K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$16.5K
3
Renaissance Technologies
Renaissance Technologies
New York
+$8.57K
4
VF
Virtu Financial
New York
+$7.97K

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$217K
2
TSS
Two Sigma Securities
New York
-$30.7K
3
RJFSA
Raymond James Financial Services Advisors
Florida
-$24.5K
4
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
-$23K
5
BlackRock
BlackRock
New York
-$17.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
1
Walleye Capital
New York
$182K -$217K -735 -50%
Vanguard Group
2
Vanguard Group
Pennsylvania
$180K – – –
Citadel Advisors
3
Citadel Advisors
Florida
$141K +$167K +566 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$34.2K – – –
CBA
5
Coastal Bridge Advisors
Connecticut
$26.1K – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$23K +$8.57K +29 +47%
State Street
7
State Street
Massachusetts
$21.3K – – –
Millennium Management
8
Millennium Management
New York
$17.5K -$9.16K -31 -31%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$14K +$16.5K +56 New
VF
10
Virtu Financial
New York
$13K +$7.97K +27 +104%
VCA
11
Verdence Capital Advisors
Maryland
$9.96K -$2.95K -10 -20%
MCP
12
Mirador Capital Partners
California
$9.33K -$886 -3 -7%
Northern Trust
13
Northern Trust
Illinois
$7.66K – – –
TSS
14
Two Sigma Securities
New York
$5.32K -$30.7K -104 -83%
TRCT
15
Tower Research Capital (TRC)
New York
$4.38K – – –
Wells Fargo
16
Wells Fargo
California
$1.6K – – –
AF
17
Allworth Financial
California
$846 – – –
BlackRock
18
BlackRock
New York
$146 -$17.1K -58 -98%
RJFSA
19
Raymond James Financial Services Advisors
Florida
– -$24.5K -98 Closed
Janney Montgomery Scott
20
Janney Montgomery Scott
Pennsylvania
– -$23K -92 Closed
UBS Group
21
UBS Group
Switzerland
– -$11.2K -45 Closed
Jane Street
22
Jane Street
New York
– -$5.02K -20 Closed
WP
23
WealthPLAN Partners
Nebraska
– -$500 -2 Closed
FFA
24
Farther Finance Advisors
California
– -$244 -1 Closed

PCSA Hedge Fund Activity: Q2 2023 in Review

18 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2023, worth a combined $691K — down 19% from $853K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of PCSA and 2 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 2 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $167K. The largest seller was Walleye Capital, cutting an estimated $217K.

  • 18 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2023, down from 22 in Q1 2023.
  • Funds reported $691K of Processa Pharmaceuticals stock for Q2 2023, down 19% quarter-over-quarter.
  • 2 funds opened new Processa Pharmaceuticals positions in Q2 2023 and 6 closed out, a net change of -4 holders.
  • The largest Processa Pharmaceuticals buyer in Q2 2023 was Citadel Advisors, an estimated $167K added.
  • The largest Processa Pharmaceuticals seller in Q2 2023 was Walleye Capital, an estimated $217K sold.

Based on aggregated 13F filings for Q2 2023.